Shire Pharmaceuticals Group PLC 10% Owner | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website
  • Reminder to Premium Members: To enjoy full site functionality & avoid the bugs currently affecting recommend, delete & other features on our "www" pages, please log in to your premium accounts at https://premium.investorvillage.com If you need assistance, don't hesitate to contact customer support any time. That's a big part of what you pay for, after all!  


IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49606 of 49715  at  6/17/2019 10:35:49 AM  by

Biotechbeagle


 In response to msg 49605 by  kycats
view thread

Re: Shire Pharmaceuticals Group PLC 10% Owner

I first learned of it on this website - http://www.j3sg.com/Register/processforgotEmail2.php?email=pmalyak@gmail.com&Submit=Go

Below is the actual filing. Maybe that's how Enyedy and Blaine McKee were positioned at IMGN. The filing shows they bought warrants in 2002.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 3

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)
________________________________________________________________________________
1. Name and Address of Reporting Person*

Shire BioChem Inc.
--------------------------------------------------------------------------------
(Last) (First) (Middle)

275 Armand-Frapper Blvd.
--------------------------------------------------------------------------------
(Street)

Lavel (Quebec) Canada H7V 4A7
--------------------------------------------------------------------------------
(City) (State) (Zip)

________________________________________________________________________________
2. Date of Event Requiring Statement (Month/Day/Year)

June 29, 2002
________________________________________________________________________________
3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)


________________________________________________________________________________
4. Issuer Name and Ticker or Trading Symbol

ImmunoGen, Inc. (IMGN)
________________________________________________________________________________
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

|_| Director |_| 10% Owner
|_| Officer (give title below) |X| Other (specify below)

See Explanation of Responses below.
________________________________________________________________________________
6. If Amendment, Date of Original (Month/Day/Year)


________________________________________________________________________________
7. Individual or Joint/Group Filing (Check Applicable line)

|_| Form filed by One Reporting Person

|X| Form filed by More than One Reporting Person

================================================================================
Table I -- Non-Derivative Securities Beneficially Owned
================================================================================

<TABLE>
<CAPTION>
3. Ownership Form:
2. Amount of Securities Direct (D) or
1. Title of Security Beneficially Owned Indirect (I) 4. Nature of Indirect Beneficial Ownership
(Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>


------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

====================================================================================================================================
</TABLE>


<PAGE>


FORM 3 (continued)

Table II -- Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

================================================================================

<TABLE>
<CAPTION>
5. Owner-
3. Title and Amount of Securities ship
Underlying Derivative Security Form of
2. Date Exercisable (Instr. 4) Derivative
and Expiration Date --------------------------------- 4. Conver- Securities:
(Month/Day/Year) Amount sion or Direct 6. Nature of
---------------------- or Exercise (D) or Indirect
Date Expira- Number Price of Indirect Beneficial
1. Title of Derivative Exer- tion of Derivative (I) Ownership
Security (Instr. 4) cisable Date Title Shares Security (Instr. 5) (Instr. 5)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>

Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D
------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 356,297 $2.366 D

------------------------------------------------------------------------------------------------------------------------------------
Warrant (Right to
buy)(1) 7/31/2000 7/31/2002 Common Stock 782,755 $2.366 D

====================================================================================================================================
</TABLE>


Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

Explanation of Responses:

(1) Prior to July 29, 2002, Shire BioChem, a wholly owned subsidiary of Shire
Pharmaceuticals Group Plc, was the owner of the warrants listed above, the terms
of exercise of which, as to the number of shares, varied with the market price
of the common stock. On June 29, 2002, Shire BioChem Inc. could have exercised
the warrants listed above for more than 10% of the Immunogen, Inc. common stock
based on the average closing price per share of the common stock for the five
consecutive trading days preceding such date, which was $2.366. Upon Shire
BioChems' exercise of the warrants on July 29, 2902, and at all times since,
Shire BioChem has beneficially owned less than 10% of Immunogen's common stock.



/s/ Joseph Rus October 3, 2002
--------------------------------------------- -----------------------
**Signature of Reporting Person Date
Name: Joseph Rus
Title: President and Chief Executive Officer

* If the form is filed by more than one reporting person, see Instruction
5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space is insufficient, see Instruction 6 for procedure.



<PAGE>

Joint Filer Information


Name: Shire Pharmaceuticals Group plc

Address: Hampshire International Business Park
Chineham, Basingstoke
Hampshire, England RG24 8EP

Designated Filer: Shire BioChem Inc.

Issuer & Ticker Symbol: ImmunoGen, Inc. (IMGN)

Date of Event Requiring Statement: June 29, 2002


Signature: /s/ Angus Charles Russell
--------------------------------------------
Name: Angus Charles Russell
Title: Group Finance Director


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 230
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
49607 Re: Shire Pharmaceuticals Group PLC 10% Owner Bibliobiftek 0 6/17/2019 11:07:29 AM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...